Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
28/2 23:15
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.77. This compares to loss of $1.25 per share a year ago. These figures are adjusted for non-recurring items....